Nektar Therapeutics (NKTR) Net Cash Flow Growth (1y) (2011 - 2026)
Nektar Therapeutics (NKTR) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.60% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,421.76% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 149.49% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -100.75% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -104.22% |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | 2,610.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,610.02% |
| Dec 31, 2025 | -283.67% |
| Sep 30, 2025 | -189.08% |
| Jun 30, 2025 | 119.75% |
| Mar 31, 2025 | -140.06% |
| Dec 31, 2024 | 147.59% |
| Sep 30, 2024 | -84.63% |
| Jun 30, 2024 | 21.39% |
| Mar 31, 2024 | 218.17% |
| Dec 31, 2023 | -68.61% |
| Sep 30, 2023 | -49.87% |
| Jun 30, 2023 | -373.69% |
| Mar 31, 2023 | -126.45% |
| Dec 31, 2022 | 38.91% |
| Sep 30, 2022 | 129.00% |
| Jun 30, 2022 | 333.81% |
| Mar 31, 2022 | 187.74% |
| Dec 31, 2021 | -120.12% |
| Sep 30, 2021 | -3,870.23% |
| Jun 30, 2021 | 101.31% |